Literature DB >> 22550272

Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.

Vera P Krymskaya.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22550272      PMCID： PMC3359910          DOI： 10.1165/rcmb.2011-0381ED

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN： 1044-1549            Impact factor:   6.914


× No keyword cloud information.
  43 in total

1.  Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Poay N Lim; Daniel Noonan; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-30       Impact factor: 6.914

2.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Authors:  T Carsillo; A Astrinidis; E P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

Authors:  Angelo M Taveira-DaSilva; Mario P Stylianou; Carolyn J Hedin; Olanda Hathaway; Joel Moss
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

4.  Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.

Authors:  Andrey Parkhitko; Faina Myachina; Tasha A Morrison; Khadijah M Hindi; Neil Auricchio; Magdalena Karbowniczek; J Julia Wu; Toren Finkel; David J Kwiatkowski; Jane J Yu; Elizabeth Petri Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

5.  Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis.

Authors:  Xiaoning Zhe; Lucia Schuger
Journal:  J Histochem Cytochem       Date:  2004-12       Impact factor: 2.479

Review 6.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

7.  Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

Authors:  Laifong Lee; Paul Sudentas; Brian Donohue; Kirsten Asrican; Aelaf Worku; Victoria Walker; Yanping Sun; Karl Schmidt; Mitchell S Albert; Nisreen El-Hashemite; Alan S Lader; Hiroaki Onda; Hongbing Zhang; David J Kwiatkowski; Sandra L Dabora
Journal:  Genes Chromosomes Cancer       Date:  2005-03       Impact factor: 5.006

8.  Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells.

Authors:  Jane J Yu; Victoria A Robb; Tasha A Morrison; Eric A Ariazi; Magdalena Karbowniczek; Aristotelis Astrinidis; Chunrong Wang; Lisa Hernandez-Cuebas; Laura F Seeholzer; Emmanuelle Nicolas; Harvey Hensley; V Craig Jordan; Cheryl L Walker; Elizabeth P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

9.  Rodent model of reproductive tract leiomyomata. Clinical and pathological features.

Authors:  J I Everitt; D C Wolf; S R Howe; T L Goldsworthy; C Walker
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

10.  TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase.

Authors:  Elena Goncharova; Dmitry Goncharov; Daniel Noonan; Vera P Krymskaya
Journal:  J Cell Biol       Date:  2004-12-20       Impact factor: 10.539
View more
  9 in total

1.  Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis.

Authors:  Chenggang Li; Na Li; Xiaolei Liu; Erik Y Zhang; Yang Sun; Kouhei Masuda; Jing Li; Julia Sun; Tasha Morrison; Xiangke Li; Yuanguang Chen; Jiang Wang; Nagla A Karim; Yi Zhang; John Blenis; Mauricio J Reginato; Elizabeth P Henske; Jane J Yu
Journal:  JCI Insight       Date:  2016-11-17

2.  Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Melane Fehrenbach; Irene Khavin; Blerina Ducka; Okio Hino; Thomas V Colby; Mervyn J Merrilees; Angela Haczku; Steven M Albelda; Vera P Krymskaya
Journal:  Sci Transl Med       Date:  2012-10-03       Impact factor: 17.956

3.  Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Authors:  Yang Sun; Dana Gallacchi; Erik Y Zhang; Samuel B Reynolds; Lauren Robinson; Izabela A Malinowska; Terry T Chiou; Ana M Pereira; Chenggang Li; David J Kwiatkowski; Po-Shun Lee; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2014-12       Impact factor: 6.914

4.  Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.

Authors:  Elena N Atochina-Vasserman; Dmitry A Goncharov; Alla V Volgina; Megan Milavec; Melane L James; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2013-11       Impact factor: 6.914

Review 5.  Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Stephen R Hammes; Vera P Krymskaya
Journal:  Horm Cancer       Date:  2012-11-27       Impact factor: 3.869

6.  Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.

Authors:  Chenggang Li; Po-Shun Lee; Yang Sun; Xiaoxiao Gu; Erik Zhang; Yanan Guo; Chin-Lee Wu; Neil Auricchio; Carmen Priolo; Jing Li; Alfredo Csibi; Andrey Parkhitko; Tasha Morrison; Anna Planaguma; Shamsah Kazani; Elliot Israel; Kai-Feng Xu; Elizabeth Petri Henske; John Blenis; Bruce D Levy; David Kwiatkowski; Jane J Yu
Journal:  J Exp Med       Date:  2014-01-06       Impact factor: 14.307

7.  Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.

Authors:  Elena A Goncharova; Melane L James; Tatiana V Kudryashova; Dmitry A Goncharov; Vera P Krymskaya
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

8.  Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis.

Authors:  Fatemeh Aghaeimeybodi; Katayoun Najafizadeh; Seyd-Kazem Razavi-Ratki; Nasim Namiranian
Journal:  Caspian J Intern Med       Date:  2019

9.  Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM).

Authors:  Vera P Krymskaya
Journal:  Expert Opin Orphan Drugs       Date:  2014-08-27       Impact factor: 0.694
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.